Retrospective Study
Copyright ©The Author(s) 2018.
World J Cardiol. Apr 26, 2018; 10(4): 21-25
Published online Apr 26, 2018. doi: 10.4330/wjc.v10.i4.21
Table 1 Patient demographics at the start of wearable cardioverter defibrillator use
ParameterAll (n = 257)Not serious (n = 56)Serious (n = 201)
Age, yr (median, range)69 (25-90)69 (25-82)69 (39-90)
Sex
Male (%)191 (74.3)41 (73.2)150 (74.6)
Female65 (25.3)15 (26.8)50 (24.9)
NA1 (0.4)0 (0)1 (0.5)
LVEF % (median, range) (n = 241 reported)25 (10-65)25 (10-65)27.5 (10-60)
Primary indication, n (%)
MI/NICM198 (77.0)43 (76.8)155 (77.1)
ICD Explant22 (8.6)6 (10.7)16 (8.0)
VT/SCA35 (13.6)7 (12.5)28 (13.9)
Genetic risk1 (0.4)0 (0)1 (0.5)
NA1 (0.4)0 (0)1 (0.5)
History of diabetes mellitus
Yes128 (49.8)18 (32.1)110 (54.7)c
No111 (43.2)38 (67.9)73 (36.3)
NA18 (7.0)0 (0)18 (9.0)
History of ESRD/HD
Yes34 (13.2)5 (8.9)29 (14.4)
No204 (79.4)51 (9.1)153 (76.1)
NA19 (7.4)0 (0)19 (9.5)
History of arrhythmias123754183
Patients reported
Any arrhythmia listed below169 (71.3)41 (75.9)128 (69.9)
Sustained VT/VF68 (28.7)19 (35.2)49 (26.8)
Bundle branch block49 (20.7)18 (33.3)b31 (16.9)
AFib/Aflutter/SVT/AT98 (41.4)23 (42.6)75 (41.0)
Bradycardia/Heart Block/PEA31 (13.1)6 (11.1)25 (13.7)
Table 2 Wearable cardioverter defibrillator discontinuation among acute survivors
ReasonPatients [n = 108, n (%)]Days post-asystole (median, range)
Received ICD or pacemaker48 (44.4)4 (0-175)
Condition improved17 (15.7)39 (3-525)
Condition deteriorated10 (9.3)4 (0-44)
Patient decision5 (4.6)73 (12-80)
Unknown/other5 (4.6)33 (0-96)
Died22 (20.4)4 (0-44)
Still wearing1 (0.9)NA